54 stories
Obesity coverage on Peptide News Digest follows the drugs that actually reshape body weight at scale: GLP-1 agonists, GIP/GLP-1 dual and triple agonists, amylin combinations, and the next layer behind them.
Headline reads from 2025 and 2026: SURMOUNT-5 (tirzepatide vs semaglutide head-to-head), ACHIEVE-3 (orforglipron in obesity), REDEFINE-1 (CagriSema), the SELECT cardiovascular outcomes trial in non-diabetic adults with obesity, and a steady stream of real-world evidence showing the gap between trial weight loss and 12-month routine-care outcomes. Adherence and discontinuation are now the most cited weak points in the category.
The other half of obesity coverage is access — payer policy, Medicare and CMS rulings, the compounding economy, telehealth distribution, and the OMA conference circuit. Browse the latest below.
Motley Fool analysis argues that retatrutide — Lilly's triple GLP-1/GIP/glucagon agonist showing up to 28.7% weight loss in Phase 3 TRIUMPH-4 — is the one thing that could firmly cement Lilly's dominance in the obesity drug market. With seven additional Phase 3 readouts expected in 2026 and a projected 2028 launch, retatrutide positions Lilly to extend its lead over Novo Nordisk.
Stanford scientists used AI to identify BRP, a naturally occurring peptide that acts directly on the hypothalamus to suppress appetite — avoiding the gut-related side effects of current GLP-1 drugs. In animal studies, BRP reduced body weight and fat without nausea, constipation, or muscle loss. Published in Nature, with human trials planned.
A poster at the Obesity Medical Association annual conference (April 10-12, San Diego) showed tirzepatide achieved greater body weight reduction than semaglutide at 12 months in a real-world Truveta EHR analysis of adults with obesity without diabetes, consistent with SURMOUNT-5 clinical trial results.
The American Diabetes Association published new pharmacologic obesity treatment standards in its journal Diabetes, Obesity, and Cardiometabolic Care, calling on clinicians and policymakers to eliminate weight stigma. Over 40% of people with class II obesity report weight-based discrimination that impedes treatment access.
Eli Lilly's triple-agonist retatrutide met all primary and key secondary endpoints in Phase III TRIUMPH-4. The 9mg and 12mg doses achieved significant weight loss and knee pain reduction at 68 weeks in patients with obesity and osteoarthritis. Seven more Phase III readouts expected in 2026.
The Atlantic examines how GLP-1 pills are reshaping obesity treatment. The shift from weekly injections to daily pills addresses a major compliance barrier, though patients must continue therapy indefinitely.
Over 80 pharmaceutical companies are running clinical trials in obesity. Boehringer Ingelheim is advancing survodutide into three global Phase III trials, positioning it as a key next-generation GLP-1 competitor.
Novo Nordisk's long-acting amylin analog produced significant weight loss as standalone treatment in a 68-week double-blind trial, strengthening its profile ahead of the CagriSema FDA decision.
Phase IIIb results show investigational 7.2 mg semaglutide dose produced 21% mean weight loss in adults with obesity without diabetes, with a tolerable safety profile.
BioSpace reports Lilly launched Foundayo with $1.5 billion in pre-built inventory. Available via LillyDirect with prescriptions accepted immediately and shipping beginning April 6.
The FDA approved Foundayo, a once-daily oral GLP-1 pill that can be taken any time without food or water restrictions. In trials, patients lost an average of 11% body weight over one year. It was approved under the FDA's National Priority Voucher program.
Findings presented at The Liver Meeting show retatrutide cleared fatty liver disease in more than 85% of patients with obesity, dramatically expanding its therapeutic profile beyond weight loss.
Novo Nordisk's amylin analog peptide showed significant weight loss as standalone treatment in Phase 3 trial data, positioning it as a new pillar in peptide-based obesity treatment.
AstraZeneca has oral GLP-1 agents (AZD5004), peptide therapies (AZD6234), and dual agonist combinations in its Phase II obesity pipeline.
Eli Lilly's triple-agonist achieved record weight loss at the highest dose with substantial reductions in knee osteoarthritis pain. Seven more Phase 3 trials expected in 2026.
Analysis of the TRIUMPH program (TRIUMPH-1 through TRIUMPH-4) published in Diabetes, Obesity, and Metabolism shows unprecedented average weight reduction of up to 24% across 5,800+ adults.
Phase 3 trial results show cagrilintide, an amylin analogue peptide, achieved significant weight loss as a standalone therapy — a new peptide-based approach distinct from GLP-1 agonists.
Novo Nordisk signed a deal worth up to $2.1 billion with Vivtex Corporation, an MIT spinoff co-founded by Bob Langer, to develop next-generation oral biologic medicines for obesity and diabetes. Vivtex's AI-driven platform screens thousands of drug delivery formulations per day with near-perfect correlation to human intestinal absorption.